organization · Reporting owner
Ezbon International Ltd
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akero Therapeutics, Inc.
Report date December 01, 2022 · Filed December 05, 2022
Jointly reported with Skorpios Trust, Blue Horizon Enterprise Ltd, Montrago Trustees Ltd
Section 16 reporting ended · disclosed 2022-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,271,829 |
Reported balance
After 2022-12-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-12-01 · Sale · Disposed 1,636,000 · Balance 3,271,829 F1: Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 2,346,298 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 925,531 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 2,346,298 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 925,531 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein.
Stoke Therapeutics, Inc.
Report date June 04, 2025 · Filed June 06, 2025
Jointly reported with Skorpios Trust, Blue Horizon Enterprise Ltd, Montrago Trustees Ltd
Section 16 reporting ended · disclosed 2025-06-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,906,181 |
Reported balance
After 2025-06-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-06-04 · Sale · Disposed 3,000,000 · Balance 3,906,181 F1: Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 2,967,621 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 938,560 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 2,967,621 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 938,560 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2025 Filed Jun 6, 2025 16:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,000,000 | $10.20 | $30,600,000.00 |
DisclosureSEC source: 0001062993-25-011153 · form4.xml · nonDerivative · entry 1 Skorpios Trust · CIK 0001869333 · 10% owner Blue Horizon Enterprise Ltd · CIK 0001869057 · 10% owner Ezbon International Ltd · CIK 0001869027 · 10% owner Montrago Trustees Ltd · CIK 0001869331 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,906,181 F1 · ownership.nature: Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 2,967,621 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 938,560 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein. Read SEC document |
| December 23, 2024 Filed Dec 27, 2024 17:13 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,000,000 | $11.50 | $23,000,000.00 |
DisclosureSEC source: 0001062993-24-021228 · form4.xml · nonDerivative · entry 1 Skorpios Trust · CIK 0001869333 · 10% owner Blue Horizon Enterprise Ltd · CIK 0001869057 · 10% owner Ezbon International Ltd · CIK 0001869027 · 10% owner Montrago Trustees Ltd · CIK 0001869331 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 6,906,181 F1 · ownership.nature: Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 2,967,621 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 3,938,560 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 16:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,937,500 | $14.05 | $27,221,875.00 |
DisclosureSEC source: 0001062993-24-016894 · form4.xml · nonDerivative · entry 1 Skorpios Trust · CIK 0001869333 · 10% owner Blue Horizon Enterprise Ltd · CIK 0001869057 · 10% owner Ezbon International Ltd · CIK 0001869027 · 10% owner Montrago Trustees Ltd · CIK 0001869331 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 8,906,181 F1 · ownership.nature: Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 4,967,621 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 3,938,560 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 17, 2024 Filed Apr 18, 2024 16:16 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,600,000 | $11.60 | $41,760,000.00 |
DisclosureSEC source: 0001062993-24-008547 · form4.xml · nonDerivative · entry 1 Skorpios Trust · CIK 0001869333 · 10% owner Blue Horizon Enterprise Ltd · CIK 0001869057 · 10% owner Ezbon International Ltd · CIK 0001869027 · 10% owner Montrago Trustees Ltd · CIK 0001869331 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 10,843,681 F1 · ownership.nature: Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 6,905,121 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 3,938,560 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 16:36 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 1,636,000 | $43.50 | $71,166,000.00 |
DisclosureSEC source: 0001062993-22-023333 · form4.xml · nonDerivative · entry 1 Skorpios Trust · CIK 0001869333 · Former 10% owner Blue Horizon Enterprise Ltd · CIK 0001869057 · Former 10% owner Ezbon International Ltd · CIK 0001869027 · Former 10% owner Montrago Trustees Ltd · CIK 0001869331 · Former 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,271,829 F1 · kind: Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 2,346,298 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 925,531 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein. F1 · ownership.nature: Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 2,346,298 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 925,531 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.